Form 4: United Therapeutics EVP Converts Performance RSUs

United Therapeutics' EVP & General Counsel, Paul A. Mahon, reported the vesting and conversion of restricted stock units into common stock, with a portion withheld for taxes.

Summary

• Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp (UTHR), reported changes in beneficial ownership of common stock.
• On March 15, 2026, 8,895 and 7,796 performance-based Restricted Stock Units (RSUs) vested and converted into common stock, totaling 16,691 shares acquired.
• These RSUs were originally granted on March 15, 2023.
• Concurrently, 4,457 shares and 3,906 shares (totaling 8,363 shares) were disposed of at a price of $536.12 per share to cover tax obligations related to the RSU vesting.
• All reported transactions were conducted under a Rule 10b5-1 trading plan.
• Following these transactions, Paul A. Mahon beneficially owns 45,172 shares of United Therapeutics common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the vesting of performance-based RSUs implies the company met certain performance targets, reflecting positively on past operational success, though it's a routine compensation event.

Positives

• The vesting of performance-based restricted stock units indicates the achievement of specific performance targets set when the RSUs were granted in March 2023.
• The transactions were executed under a Rule 10b5-1 plan, demonstrating pre-planned and compliant insider trading practices.

Negatives

• A total of 8,363 shares were disposed of to cover tax liabilities, which, while a common practice, reduces the insider's direct equity holding in the company.

Future Outlook

This filing does not contain forward-looking statements or guidance; it reports past insider transactions.

Industry Context

StockSavvy.ai notes that the vesting of performance-based restricted stock units is a common component of executive compensation packages in the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance. The use of a 10b5-1 plan for these transactions is standard practice for managing insider stock sales compliantly.

Comparison to Industry Standards

• The RSU vesting and subsequent tax-related sales are standard practice for executive compensation in the biotech sector.
• Companies like Amgen (AMGN) and Gilead Sciences (GILD) frequently report similar Form 4 filings for their executives, where performance-based equity awards vest, and a portion is sold to cover statutory tax obligations.
• The share price of $536.12 reflects the market valuation of United Therapeutics at the time of the transaction, which is a strong valuation for a biotech company.

Stakeholder Impact

• Shareholders: The vesting of performance-based RSUs suggests the company achieved certain performance metrics, which could be viewed positively. The sale of shares for tax purposes is a routine event and has minimal direct impact on the broader shareholder base.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions related to executive compensation (RSU vesting and tax withholding). It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and compliant, thus a 'hold' recommendation is appropriate as there's no new catalyst for 'buy' or 'sell'.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Paul A. Mahon, 10b5-1 Plan